HC Wainwright & Co. Reiterates Neutral on Karuna Therapeutics, Maintains $330 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Neutral rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a $330 price target.

March 11, 2024 | 11:25 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Karuna Therapeutics maintains a Neutral rating and a $330 price target by HC Wainwright & Co.
The reiteration of a Neutral rating and maintenance of a $330 price target by a reputable analyst firm like HC Wainwright & Co. suggests stability in the analyst's view towards Karuna Therapeutics. This stability is likely to have a neutral short-term impact on the stock price, as it does not introduce new positive or negative information but confirms the existing valuation and outlook.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100